News | March 30, 2015

Medicines Company Receives European Commission Approval for Cangrelor and Raplixa Sealant Powder

Marketing authorization for antiplatelet agent and blood clotting mixture valid in 31 countries of the European Economic Area

March 30, 2015 — The Medicines Company announced that the European Commission has granted marketing authorization for two acute care products – Kengrexal (cangrelor) and Raplixa (sealant powder). These approvals follow the issuance of positive opinions in January by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The marketing authorization for each of these products is now valid in the 31 countries of the European Economic Area (EEA), which includes all 28 European Union (EU) Member States, plus Norway, Iceland and Liechtenstein.

Kengrexal is a bioavailable, quickly reversible intravenous small molecule antiplatelet agent to prevent platelet activation and aggregation that leads to thrombosis in the acute care setting, including in patients undergoing percutaneous coronary intervention (PCI). Raplixa is a mixture of two essential blood clotting proteins, fibrinogen and thrombin, formulated as a unique dry powder topical hemostatic product.

Prof. Philippe Gabriel Steg, M.D., director of the Coronary Care Unit, Hôpital Bichat-Claude Bernard, Paris, France, stated, “The availability of a potent, injectable, and reversible antiplatelet agent will be an important adjunct to our therapeutic armamentarium to reduce peri-procedural complications and help make PCI safer. It will be useful in a variety of settings from acute myocardial infarction to elective PCI, mostly in patients in whom antiplatelet agents have either not been administered or are known to be poorly effective.”

Prof. Wolf O. Bechstein, M.D., Ph.D., professor of surgery, Hospital of the Johann Wolfgang Goethe University, Frankfurt, Germany, noted, “I am pleased to see that Raplixa is approved throughout Europe. We were very fond of the product during the Phase 3B trial and look forward to using it in everyday practice. This will be an important new and innovative product for us to use in hemostasis treatment.”

The company used a centralized regulatory procedure, which allows applicants to obtain authorization for marketing throughout the EU, subject to national pricing and reimbursement processes. “Some member states such as England will allow marketing immediately,” said Stephanie Plent, M.D., executive vice president and chief value officer, The Medicines Company. “Other countries require pricing and reimbursement to be negotiated first, and that process is underway.”

Commercialization of each product will be directed by the company’s Global Innovation Groups, with European coordination via the company’s Zurich-based offices. The company will also begin finalizing logistics for product packaging and distribution channels for Europe. In addition, the company anticipates partnering with leading firms in Europe to provide the necessary field-based educational and promotional resources at a national and/or regional level.

A new drug application for Kengrexal (cangrelor) and a biologics license application for Raplixa are under active review by the U.S. Food and Drug Administration.

For more information: www.themedicinescompany.com

Related Content

Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals | May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals | April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
synthetic HDL-C injection, cholesterol, arterial plaque, heart attack patients, CARAT trial, ACC.17, clinical study
News | Pharmaceuticals | March 29, 2017
Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good cholesterol, into the...
Overlay Init